This webinar, co-hosted by Phenomenex and the Bio-Analytical Separation Science Group at Vrije Universiteit Brussel, will delve into actionable insights into optimizing impurity profiling workflows. The speakers will showcase the potential of ion-pair reversed-phase liquid chromatography coupled with mass spectrometry (IP-RPLC-MS) for high-throughput and high-resolution impurity profiling to enhance the efficacy and safety of oligonucleotide therapeutics. These oligonucleotide therapeutics offer precise gene modulation for tackling rare genetic diseases, with 23 confirmed FDA-approved therapies.
The speaker will explore how base, ribose, and phosphate modifications enhance therapeutic performance by improving binding affinity, thermostability, and nuclease resistance. Further, they will identify and characterize key impurities such as shortmers and phosphodiester byproducts, while exploring methodological strategies to optimize their analysis to ensure more reliable and effective drug development.
Attendees will gain practical insights into optimizing impurity profiling workflows, helping them enhance the quality and safety of their oligonucleotide therapeutics. If you’re involved in CGT development, this session will equip you with actionable tools to streamline your analysis and stay ahead in this rapidly evolving field.